Navigation Links
Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No

The FDA has given its consent for the novel version of the allergy medicine, Clarinex-D 12 Hour, to alleviate nasal, non nasal symptoms and nasal congestion occurring in adults and children above the age of 12. According to the // researchers, this medicine will be in time for the spring allergy season.

It is estimated that about 36 million people in the U.S. are troubled by seasonal allergies with apparent runny nose, sneezing, nasal congestion, and itchy, watery eyes, symptoms.

Clarinex (desloratadine) , used for treatment of seasonal allergy symptoms, is a nonsedating antihistamine procured only by prescription . Approval for Clarinex-D 24 Hour (containing 5 milligrams desloratadine and 240 milligrams pseudo ephedrine), prescribed only once a day was obtained last spring. Clarinex-D 12 hour, the recently approved medicine contains 2.5 milligrams desloratadine and 120 milligrams pseudo ephedrine, and can be consumed twice a day.

The FDA approval was close on the heels of two clinical trials involving 1,200 people or more who suffered seasonal allergies. The trails involved comparison of the treatment with Clarinex-D 12 HOUR extended-release tablets with pseudoephedrine alone and desloratadine alone. The results depicted that the extended-release-combined medication eased nasal congestion as well as provided immense relief compared to desloratadine alone, relieving other allergy symptoms better than pseudoephedrine alone.

Insomnia, headache, dry mouth, and fatigue are some of the common side effects associated with Clarinex-D 12 Hour use. This medicine should not be taken by those suffering from narrow-angle glaucoma, severe high blood pressure or heart disease, urination difficulty, or by patients who may have taken a monoamine-oxidase inhibitor 14 days prior to the use of this drug. It also recommended that those with certain other medical conditions such as high blood pressure, diabetes, heart disease, thyroid, liver , or kidney problems, or enlarged prostate should seek the advice of a medical specialist before resorting to the use of Clarinex-D 12 hour or Clarinex-D 24 Hour.


'"/>




Related medicine news :

1. British Doctor cleared of murder
2. Mist over a way to help premature babies breathes cleared!
3. Business model for Liver Institute cleared by Delhi Cabinet
4. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
5. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
6. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
7. US Doctors Association Gives away $110,000 To NGO’
8. Woman In Coma Gives Birth To Daughter
9. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
10. New Eye Surgery Gives Hope To Short-Sighted
11. Jharkhand Gives Health industry status
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology: